Trials / Withdrawn
WithdrawnNCT05678283
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
A Phase 1, 2-Part, Open-label Study to Determine the Absorption, Metabolism, and Elimination of [14C]CC-90010 in Participants With Advanced Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the absorption, metabolism, and elimination of CC-90010 and its metabolites following a single oral dose of radiolabeled CC-90010 in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]CC-90010 | Specified dose on specified days |
| DRUG | CC-90010 | Specified dose on specified days |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2024-04-29
- Completion
- 2024-04-29
- First posted
- 2023-01-10
- Last updated
- 2024-04-17
Locations
1 site across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05678283. Inclusion in this directory is not an endorsement.